Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus (RISE)

Study:

A Phase III, Double-Masked, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus

Rationale:

n/a

Purpose:

This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection in patients with CSME-CI secondary to diabetes mellitus (Type 1 or 2).

Study Status: Recruiting

Recruiting:
Laura Holody 216-445-3762 holodyl@ccf.org

Condition Intervention Phase
Macular Edema Drug: Ranibizumab Injection Phase 3

Verified by Genentech October, 2007

Sponsored by: Genentech
Information provided by: Genentech
ClinicalTrials.gov identifier: NCT00473330

Study Type: Interventional

Study Design: Treatment

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

Tsontcho Ianchulev, M.D., M.P.H.., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site